BMS drug Opdivo lands FDA approval for gastro cancers By Jenni Spinner The therapeutic has been approved as an adjuvant treatment for varieties of esophageal cancers in patients who have received neoadjuvant chemoradiotherapy.
Bristol Myers Squibb (BMS) announced the US Food and Drug Administration (FDAP has approved Opdivo (nivolumab, injection for intravenous use) for adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). The approval is based upon results from the recent Phase III CheckMate -577 trial, which evaluated the drug in comparison to placebo in esophageal or GEJ cancer patients with residual pathologic disease following neoadjuvant CRT and complete resection.
In CheckMate -577, Opdivo
1
Approval expands the role of Opdivo in earlier stages of disease, with two indications in the adjuvant setting across three types of cancer
1
PRINCETON, NJ, USA I May 20, 2021 I Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved
Opdivo
® (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
1 The approval is based on results from the Phase 3 CheckMate -577 trial that evaluated
Opdivo (n=532) compared to placebo (n=262) in esophageal or GEJ cancer patients with residual pathologic disease following neoadjuvant CRT and complete resection.
With No Medicaid Expansion in Sight, Hospitals and Nonprofits Fill the Coverage Gap
The North Texas Healthcare Coverage Collaborative is providing a financial stopgap for the uninsured.
By Will Maddox
Published in
Healthcare Business
April 12, 2021
11:00 am
In addition to claiming nearly 50,000 lives in Texas, COVID-19 has resulted in job loss for thousands more. Along with a loss of income, many of these Texans lost their health insurance coverage. But a collaborative is stepping up to provide short-term assistance to those in need of coverage. The United Way of Metropolitan Dallas, the Dallas-Fort Worth Hospital Council, and the Dallas County Enroll North Texas ACA Coalition have launched the North Texas Healthcare Coverage Collaborative (NTHCC) to provide financial assistance to help purchase coverage.
Healthcare Brief (04/01/21) - D Magazine dmagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dmagazine.com Daily Mail and Mail on Sunday newspapers.
Using genetic engineering, researchers at UT Southwestern and Indiana University have reprogrammed scar-forming cells in mouse spinal cords to create new nerve cells, spurring recovery after spinal cord injury.